At the time of this release Rua Bioscience has not received the settlement funds from the the purchaser, Awa Ora Genesis Kaitiaki Harakeke Trust of Te Araroa, for the purchase of the Gisborne manufacturing facility.
The contract is for $1.3 mill and was due to be paid in full by 5pm yesterday, 30th October 2024.
The Board have received assurances from the Trust that they intend to complete the purchase of the property and have requetsed further time before settlement.
The Board is now considering their legal options in this situation and are also in parallel working with other credible parties on an alternate purchase plan.
The Board will update the market as soon as new information is received.
ENDS
The person who authorised this announcement:
Paul Naske
Chief Executive Officer
[email protected]
+64 21 445154
Revenue and profit slashed for the first half of 2025 financial year.
Gentrack boss Gary Miles says its airport subsidiary is a unique global platform.
The Deloitte Fast 50 winner's NZ unit reported chunky revenue and positive cash flow.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details